BioCryst to Present at Upcoming Investor Conferences

Rhea-AI Summary

BioCryst Pharmaceuticals (BCRX) announced its participation in several investor conferences. The company will present at the Jefferies London Healthcare Conference on November 16, 2022, at 12:00 p.m. ET. Additionally, BioCryst will take part in the virtual 5th Annual Evercore ISI HealthCONx Conference on November 29, 2022, at 8:25 a.m. ET, followed by the Piper Sandler 34th Annual Healthcare Conference in New York on November 30, 2022, at 8:30 a.m. ET. Live audio webcasts will be available on BioCryst's website, ensuring stakeholders can follow the updates easily.

RESEARCH TRIANGLE PARK, N.C., Nov. 09, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the following investor conferences:

• The Jefferies London Healthcare Conference on Wednesday, November 16, 2022, at 12:00 p.m. ET.
  
  
• The 5th Annual Evercore ISI HealthCONx Conference (virtual) on Tuesday, November 29, 2022, at 8:25 a.m. ET.
  
  
• The Piper Sandler 34^th Annual Healthcare Conference in New York on Wednesday, November 30, 2022, at 8:30 a.m. ET.
  

Links to live audio webcasts and replays of the presentations may be accessed in the Investors & Media section of BioCryst’s website at http://www.biocryst.com.

About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO^® (berotralstat) is approved in the United States and many global markets. BioCryst has active programs to develop oral medicines for multiple targets across the complement system, including oral factor D inhibitors BCX9930 and BCX10013, which are in clinical development. RAPIVAB^® (peramivir injection) is approved in the U.S. and multiple global markets, with post-marketing commitments ongoing. For more information, please visit the company’s website at www.biocryst.com.

BCRXW

Investor Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com

Media Contact:
Catherine Collier Kyroulis
+1 917 886 5586
ckyroulis@biocryst.com

FAQ

When will BioCryst Pharmaceuticals present at the Jefferies London Healthcare Conference?

BioCryst Pharmaceuticals will present at the Jefferies London Healthcare Conference on November 16, 2022, at 12:00 p.m. ET.

What is the schedule for BioCryst Pharmaceuticals at the Evercore ISI HealthCONx Conference?

BioCryst will participate in the 5th Annual Evercore ISI HealthCONx Conference virtually on November 29, 2022, at 8:25 a.m. ET.

When is the Piper Sandler Healthcare Conference where BioCryst will present?

The Piper Sandler 34th Annual Healthcare Conference, featuring BioCryst, will take place on November 30, 2022, at 8:30 a.m. ET in New York.

How can investors access the presentations from BioCryst Pharmaceuticals?

Investors can access live audio webcasts and replays of BioCryst's presentations on the Investors & Media section of the company's website.

What is the stock symbol for BioCryst Pharmaceuticals?

The stock symbol for BioCryst Pharmaceuticals is BCRX.